Many clips,
http://ow.ly/LhC1
Includes:
Video interview and audio Q&A Slamon on long-term Herceptin data (4x cardio toxicity, increased leukemia with Anthracycline disappears without) and and isolated (but significant) Anthracycline benefit to those with Her2 positive status with TOPO amplification. Very small benefit previously thought to be scattered across the board was actually major benefit in a very few with her2 & Topo. Mentions resistance by some who have made careers out of Anthracycline studies not happy about the findings.
Weinberg on EMT/Cancer stem cell connection
http://www.youtube.com/watch?v=Tmbjj6Nzo4U
Epithelial (non-motile) cells can become mesenchymal (motile/aggressive) with their stem like qualities.
Eric Winer on most effective adjuvant chemo regimens. Mentions Taxane and Anthracyclines without factoring in TOPO issue. Hormonal more important than chemo in ER+. Herceptin important addition. Move toward primacy of targeted therapy directed by tumor analysis/markers.
Kimberly Blackwell on EGF104900 Lapatinib alone or with Herceptin, heavily pretreated patients:
"Double wammy" was highly researched preclinically, delayed resistance and increased various mechanisms. 4.5 month median survival benefit in combo. Adjuvant studies in the works, thought to be promising. Combination with chemo to be investigated, but hopes future means less chemo.
Linear Mode
